Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Jay A Grobler

John A McCauley

Sherman Tim Waddell

Thomas H Graham

Michael D Miller

Tao Yu

Daria Hazuda

Deborah Anne Nicoll-Griffith

Andrew William Stamford

Osvaldo A Flores

Libo Xu

Izzat Tiedje Raheem

Hong Li

Marian Gindy

Wensheng Liu

Stephanie Elizabeth Barrett

Steven J Henry

Seth P Forster

Ryan S Teller

Wengsheng Liu

Paul D Zuck

Edward M Murray

Eric J Markel

John A Mccauley

The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.

Methods for treatment and prophylaxis of HIV and AIDS

The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is &#x2014;F or &#x2014;Cl, less frequently than once daily.

Methods for the treatment and prophylaxis of HIV and AIDS

The present invention relates to Spirocyclic Pyridotriazine Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Pyridotriazine Derivative, and methods of using the Spirocyclic Pyridotriazine Derivatives for treating or preventing HIV infection in a subject. 

Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors

The present invention relates to Amido-Substituted Pyridotriazine Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, R, RRand Rare as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Pyridotriazine Derivative, and methods of using the Amido-Substituted Pyridotriazine Derivatives for treating or preventing HIV infection in a subject. 

Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors

The present invention relates to Phosphate Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R, R, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Phosphate Substituted Quinolizine Derivative, and methods of using the Phosphate Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject. 

Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors

The present invention features methods for producing HCV replicons using HCV encoding sequences from different isolates. The featured methods are based on the discovered importance of NS3 amino acid position 470 in conferring cell culture replication activity to different HCV isolates.

Method to confer cell culture replication activity to different Hepatitis C virus isolates

The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3' UTR based on the HCV-1a 3&#x2032; UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity.

Hepatitis C virus assay systems

Growing community of inventors

Gwynedd, PA, United States of America

Jay A Grobler